Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride

Colloids and Surfaces B: Biointerfaces

Volumn 116, Issue , 2014, Pages 81-87

  Ranpise, Nisharani S ^a   Korabu, Swati S ^a   Ghodake, Vinod N ^a  

^a SINHGAD COLLEGE OF PHARMACY   (India)

Author keywords

Hypertension; In vivo pharmacodynamic study; Lercanidipine hydrochloride; Nanostructured lipid carriers; Solvent evaporation

Indexed keywords

HYPERTENSION; IN-VIVO; LERCANIDIPINE HYDROCHLORIDE; NANOSTRUCTURED LIPID CARRIERS; SOLVENT EVAPORATION;

BIOCHEMISTRY; DRUG DELIVERY; EVAPORATION; PARTICLE SIZE ANALYSIS; ZETA POTENTIAL;

PHARMACODYNAMICS;

LERCANIDIPINE; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; UNCLASSIFIED DRUG; CALCIUM; DIHYDROPYRIDINE DERIVATIVE; DRUG CARRIER; LIPID; NANOPARTICLE;

ACIDITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PH; BLOOD PRESSURE REGULATION; CHEMICAL PROCEDURES; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG INCOMPATIBILITY; DRUG PENETRATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; ENTRAPMENT EFFICIENCY; EX VIVO STUDY; FREEZE DRYING; HIGH TEMPERATURE; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHARMACODYNAMICS; PHYSICAL PARAMETERS; PRIORITY JOURNAL; RAT; SCANNING ELECTRON MICROSCOPY; SOLIDIFICATION; SOLVENT EVAPORATION; X RAY DIFFRACTION; ZETA POTENTIAL; ANIMAL; BLOOD PRESSURE; CHEMICAL STRUCTURE; CHEMISTRY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG EFFECTS; KINETICS; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; SURFACE PROPERTY;

ADMINISTRATION, ORAL; ANIMALS; BLOOD PRESSURE; CALCIUM; DIFFUSION; DIHYDROPYRIDINES; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HYPERTENSION; KINETICS; LIPIDS; MALE; MOLECULAR STRUCTURE; NANOPARTICLES; PARTICLE SIZE; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES;

EID: 84892643048     PISSN: 09277765     EISSN: 18734367     Source Type: Journal    
DOI: 10.1016/j.colsurfb.2013.12.012     Document Type: Article

References (22)

1. Das S., Chaudhary A. Recent advances in lipid nanoparticle formulations with solid matrix for oral drug delivery. AAPS PharmSciTech 2011, 12:62.
2. Mehnert W., Mader K. Solid lipid nanoparticles: production, characterization and applications. Adv. Drug Deliv. Rev. 2001, 47:165.
3. Puglia C., et al. Lipid nanoparticles for prolonged topical delivery: an in vitro and in vivo investigation. Int. J. Pharm. 2008, 357:295.
4. Muller R.H., Petersen R.D., Hommoss A., Pardeike J. Nanostructured lipid carriers (NLC) in cosmetic dermal product. Adv. Drug Deliv. Rev. 2007, 59:522.
5. Muller R.H., Maassen S., Weyhers H., Mehnert W. Phagocytic uptake and cytotoxicity of solid lipid nanoparticles sterically stabilized with poloxamine 908 and poloxamer 407. J. Drug Target. 1996, 4:161.
6. Ravi Kumar M.N. Nano and microparticles as controlled drug delivery devices. J. Pharm. Sci. 2000, 3:234.
7. Chen D.B., Yang T.Z., Lu W.L., Zhang Q. In vitro and in vivo study of two types of long circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull. 2001, 49:1444.
8. Fundaro A., Cavalli R., Bargoni A., Vighetto D., Zara G.P., Jasco M.R. Non stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after I.V. administration to rats. Pharmacol. Res. 2000, 42:337.
9. Muller R.H., Mader K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50:161.
10. Freitas C., Muller R.H. Correlation between long term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur. J. Pharm. Biopharm. 1999, 47:125.
11. Dingler A., Gohla S. Production of solid lipid nanoparticles (SLN): scaling up feasibilities. J. Microencapsul. 2002, 19:11.
12. Charman W.N. Lipids, lipophilic drugs and oral drug delivery - some emerging concepts. J. Pharm. Sci. 2000, 89:967.
13. Porter C.J.H., Charman W.N. Intestinal lymphatic drug transport an update. Adv. Drug Deliv. Rev. 2001, 50:61.
14. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J. Control. Release 2008, 127:97.
15. Chen Y., Dalwadi G., Benson H.A. Drug delivery across the blood-brain barrier. Curr. Drug Deliv. 2010, 1:537.
16. Jia L., Zhang D., Li Z., Duan C., Wang Y., Feng F., Wang F., Liu Y., Zhang Q. Nanostructured lipid carriers for parenteral delivery of silybin: biodistribution and pharmacokinetic studies. Colloid Surf. B: Biointerfaces 2010, 80:213.
17. Liu D., Liu Z., Wang L., Zhang C., Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloid Surf. B: Biointerfaces 2011, 85:262.
18. Chen C.-C., Tsai T.-H., Huang Z.-R., Fang J.-Y. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterisation and pharmacokinetics. Eur. J. Pharm. Biopharm. 2010, 74:474.
19. Liu J., Hu W., Chen H., Ni Q., Xu H., Yang X. Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int. J. Pharm. 2007, 328:191.
20. Reaven G.M., Ho H., Hoffmann B.B. Somatostatin inhibition of fructose induced hypertension. Hypertension 1989, 14:117.
21. Reaven G.M., Ho H., Hoffmann B.B. Attenuation of fructose-induced hypertension in rats by exercise training. Hypertension 1988, 12:129.
22. Bunag R.D. Validation in awake rats of a tail cuff method for measuring systolic blood pressure. J. Appl. Physiol. 1973, 34:279.